profit from every $100 of sales.
$0$100
Oruka Therapeutics
$104.99-2.03% today
+271.0% in 1 year
1-year low $26.381-year high $113.08
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Oruka Therapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Oruka Therapeutics | No profit yet | ||
 Vertex Pharmaceuticals | 34.8× · Expensive | ||
 Regeneron Pharmaceuticals | 21.8× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.3× · Fair price |
AI analysis
An AI analyst reads Oruka Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2025 |
|---|---|
| 0 | |
| – | |
| -122 | |
| -105 | |
| -105 | |
| -1.85 | |
| – | |
| – | |
| – |
Balance sheet
| In millions of USD | 2025 |
|---|---|
| Total assets | 489 |
| Cash | 47 |
| Total debt | 2 |
| Total liabilities | 20 |
| 469 | |
| 46 | |
| -17.7% | |
| -22.5% |
Cash flow
| In millions of USD | 2025 |
|---|---|
| -88 | |
| 0 | |
| -88 | |
| Dividends paid | – |
| – | |
| 24 |
Valuation
- –
- –
- –
- 6.6×
- –
- –
- –
- -1.2%
- -1.5%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -27.3%
- -23.9%
- -26.0%
- -23.0%
- -27.3%
- –
Growth
- –
- –
- −52.4%
- –
- +34.6%
Financial health
- 0.4×
- 0.00
- 0.4%
- –
- 23.76
- 23.76
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 16%of 952
Bottom 20%of 883
Bottom 32%of 985
What analysts expect
- Average price target
- $136.38
- Range
- $75.00 – $200.00
- 9 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 13, 2026 | -0.48 | -0.52 | +7.7% |
| Mar 12, 2026 | -0.45 | -0.61 | +26.2% |
| Nov 12, 2025 | -0.55 | -0.56 | +1.8% |
| Aug 11, 2025 | -0.46 | -0.48 | +4.2% |
| May 14, 2025 | -0.40 | -0.57 | +29.8% |
| Mar 6, 2025 | -0.49 | -0.68 | +27.9% |
| Nov 13, 2024 | -1.46 | -0.40 | −265.0% |
| Aug 27, 2024 | -1.53 | – | – |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
28No pass
Benjamin Graham
40No pass
Philip Fisher
32No pass
Peter Lynch
60Pass
Joel Greenblatt
0No pass
Charlie Munger
27No pass
Terry Smith
25No pass
Questions about Oruka Therapeutics
Is Oruka Therapeutics a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Oruka Therapeutics AI analysis
What does Oruka Therapeutics do?
Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA. It is in Biotechnology, based in Menlo Park, CA, United States, with 68 employees.
Does Oruka Therapeutics pay a dividend?
No. Oruka Therapeutics does not pay a dividend at the moment.
Is Oruka Therapeutics stock halal?
Yes. Oruka Therapeutics passes our halal screen: its business is permitted and its debt is under 0.1% of its market value, under the 30% limit. How we check
How has Oruka Therapeutics stock done over the past year?
Up 271.0% over the past twelve months, to $104.99. It traded between $26.38 and $113.08 and is 7.2% below its high.
Who are Oruka Therapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Oruka Therapeutics's.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.